JPRN-UMIN000025878
Completed
Phase 2
Phase II trial of nivolumab following radiation therapy to bone metastases in patients with non-small cell lung cancer - RT-Nivo NSCLC phase II
niversity of Tsukuba Hospital0 sites30 target enrollmentFebruary 1, 2017
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer with bone metastasis
- Sponsor
- niversity of Tsukuba Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Positive for epidermal grow factor receptor activating mutation or ALK re\-arrangement 2\) Active malignancies within 2 years 3\) Active infection requiring intravenous systemic therapy or hospital admission 4\) A history of interstitial lung disease 5\) A history of active, known autoimmune disease. 6\) Requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications. 7\) Active CNS metastasis 8\) Carcinomatous meningitis 9\) Positive for HBs antigen or HBV\-DNA positive 10\) Positive for HCV antibody 11\) Pregnant or breast\-feeding women 12\) Any other patients whom the doctor judged to be unsuitable for this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neckntreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynxMedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001976-39-FRGORTEC73
Active, not recruiting
Phase 1
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neckntreated squamous cell carcinoma of the head and neckMedDRA version: 26.1Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-513977-31-00Groupe Oncologie Radiotherapie Tete Cou61
Active, not recruiting
Phase 1
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003334-25-DEniversity of Cologne90
Active, not recruiting
Phase 1
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerMetastatic Malignant Neoplasm in the BrainStage IV Non-Small Cell Lung Cancer AJCC v7NCT02696993M.D. Anderson Cancer Center80
Active, not recruiting
Phase 1
A study of nivolumab in participants with metastatic or unresectable bladder cancermetastatic or unresectable urothelial cancerMedDRA version: 19.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003625-17-SEBristol-Myers Squibb International Corporation323